香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 今海醫療科技股份有限公司 （股份代號：2225） （於開曼群島註冊成立的成員有限責任公司） 董事會會議日期 Jinhai Medical Technology Limited 今海醫療科技股份有限公司 董事會主席兼執行董事 陳國寶 香港，二零二五年八月十五日 於本公告日期，董事會由八名董事組成，其中三名執行董事為陳國寶先生、王振飛 先生及李雲平先生；兩名非執行董事為蔣江雨先生及王華生先生；及三名獨立非 執行董事為嚴健軍先生、范一民先生及楊美華女士。 今海醫療科技股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈，將於二零 二五年八月二十九日舉行董事會會議，旨在考慮及批准（其中包括）刊發本公司及 其附屬公司截至二零二五年六月三十日止六個月之中期業績及派發中期股息（如 適用）。 承董事會命 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 今海醫療科技股份有限公司 呈交日期： 2025年8月15日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | | 是 | | | | 證券代號 (如上市) | 02225 | 說明 | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 本公告僅作參考用途，並不構成收購、購買或認購本公司任何證券之邀請或要約。 Jinhai Medical Technology Limited 1 對本公司股權架構的影響 下文分別列出本公司(i)緊接完成前；及(ii)緊隨完成後之股權架構： | | 緊接完成前 | | 緊隨完成後 | | | --- | --- | --- | --- | --- | | | 股份數目 | 概約百分比 | 股份數目 | 概約百分比 | | 寶來國際有限公司 | | | | | | （附註1） | 2,530,000,000 | 48.94 | 2,530,000,000 | 47.82 | | 認購人A | – | – | 40,000,000 | 0.76 | | 認購人B | – | – | 40,000,000 | 0.76 | | 認購人C | – | – | 40,000,000 | 0.76 | | 其他公眾股 ...

消息面上，今海医疗科技近期发布公告，公司(作为发行人)就认购事项与三名认购人订立三份认购协 议，以认购价每股股份1.35港元认购合共1.2亿股认购股份。各认购人为独立私人投资者。认购价为每股 股份1.35港元，较于认购协议日期联交所所报收市价每股股份1.64港元折让约17.68%；认购事项所得款 项净额(经扣除认购事项所有适用成本及开支)将约为1.6亿港元，而净发行价约为每股认购股份1.34港 元。 公告称，集团拟将认购事项所得款项用于为潜在并购医疗保健相关项目及╱或公司及投资医疗保健相关 产业提供资金；研发开支；及一般营运资金。 今海医疗科技(02225)盘中跌超36%，早盘一度跌超65%。截至发稿，跌36.11%，报1.15港元，成交额 1.61亿港元。 ...

智通财经APP获悉，今海医疗科技(02225)盘中跌超36%，早盘一度跌超65%。截至发稿，跌36.11%，报 1.15港元，成交额1.61亿港元。 消息面上，今海医疗科技近期发布公告，公司(作为发行人)就认购事项与三名认购人订立三份认购协 议，以认购价每股股份1.35港元认购合共1.2亿股认购股份。各认购人为独立私人投资者。认购价为每股 股份1.35港元，较于认购协议日期联交所所报收市价每股股份1.64港元折让约17.68%；认购事项所得款 项净额(经扣除认购事项所有适用成本及开支)将约为1.6亿港元，而净发行价约为每股认购股份1.34港 元。 公告称，集团拟将认购事项所得款项用于为潜在并购医疗保健相关项目及╱或公司及投资医疗保健相关 产业提供资金；研发开支；及一般营运资金。 ...

公司名稱: 今海醫療科技股份有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02225 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 8,000,000,000 | HKD | | 0.0025 | HKD | | 20,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 8,000,000,000 | HKD | | 0.0025 | HKD | | 20,000,000 | 本月底法定/註冊股本總額： HKD 20,000,000 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31 ...

机构评级方面，目前暂无机构对该股做出投资评级建议。 行业估值方面，支援服务行业市盈率（TTM）平均值为3.73倍，行业中值3.77倍。今海医疗科技市盈 率-82.63倍，行业排名第57位；其他中国科教产业（01756.HK）为1.47倍、光正教育（06068.HK）为 2.13倍、希教国际控股（01765.HK）为2.29倍、新高教集团（02001.HK）为2.61倍、中国新华教育 （02779.HK）为2.8倍。 资料显示，今海医疗科技股份有限公司(以下简称「本公司」)(香港交易所股票代号:2225)及其附属公司 (以下统称「本集团」)之主要业务为服务供应商,集团 KT&T Group of Companies 位於新加坡并向当地建 筑及建造承包商提供劳务派遣及配套服务,亦在当地提供宿舍服务、资讯科技服务及建造配套服务,其中 包括仓储服务、清洁服务以及楼宇保养工程等。现时集团的业务更由提供纯粹的建筑业人力及资源服 务,拓展至空间管理的综合解决方案提供商。 7月17日，截至港股收盘，恒生指数下跌0.08%，报24498.95点。今海医疗科技（02225.HK）收报1.84港 元/股，上涨11.52%，成交量4 ...

Market Performance - Today, Hong Kong stocks showed significant movements with various companies experiencing notable gains, including Now Medical Technology (02225) which rose over 5% after a partnership with David Medical to develop "Minimally Invasive 5.0" technology [1] - Semiconductor stocks also saw an uptick, with Huahong Semiconductor (01347) increasing by 4.12%, and SMIC (01347) rising by 3.11% [1][2] - Hong Kong Travel (00308) surged over 14%, doubling its stock price in less than a month, driven by speculation in the tourism industry [1] - Meituan-W (03690) rose over 3% as it led an investment in Star Sea Map, furthering its focus on embodied intelligence [1] - The insurance sector saw broad gains, with China Pacific Insurance (02601) up 4.88% and China Life Insurance (02318) increasing by 3.19% [1] Company-Specific Developments - Alibaba-W (09988) increased over 3%, although its investment in instant retail and delivery services may impact profitability, according to HSBC [2] - Qian Shi International (00381) skyrocketed by over 55% due to a proposed digital economy collaboration involving a stablecoin mechanism [2] - Stablecoin-related stocks rose, with Guotai Junan International (01788) up 9.13% and China Everbright Holdings (00165) increasing by 4.83% [2] - Yadi Holdings (01585) gained over 4% following the announcement of a new electric vehicle replacement program [3] - WuXi AppTec (02359) opened nearly 5% higher after announcing expected revenue exceeding 20 billion yuan and a projected doubling of net profit [3] Industry Trends - The electric vehicle sector is expected to see growth due to a new replacement program, which could accelerate industry expansion [3] - The rare earth sector is also experiencing upward momentum, with Jinli Permanent Magnet (06680) rising over 5% after major players announced price increases [3] - The biotechnology sector is witnessing positive developments, with Xiansheng Pharmaceutical (02096) gaining over 3% after a collaboration with Conade Biopharmaceuticals [2][3]

[Supplementary Announcement Overview](index=1&type=section&id=Supplementary%20Announcement%20Overview) This announcement provides supplementary information to the company's 2024 annual report, focusing on risk management remedies and share option scheme updates [Purpose and Background of the Announcement](index=1&type=section&id=Purpose%20and%20Background) This announcement supplements the company's 2024 annual report, detailing risk management remedies and share option scheme updates - This document is a supplementary announcement by Jinhai Medical Technology Co., Ltd. (Stock Code: 2225) regarding its 2024 annual report[2](index=2&type=chunk) - The announcement aims to provide supplementary information beyond the annual report, covering risk management, internal control, and the share option scheme[3](index=3&type=chunk)[4](index=4&type=chunk) [Risk Management and Internal Control Enhancement Measures](index=1&type=section&id=Risk%20Management%20and%20Internal%20Control%20Enhancement) The board has implemented various remedial measures to strengthen risk management and internal controls, ensuring compliance with listing rules [Details of Remedial Measures](index=1&type=section&id=Remedial%20Measures) The Board implemented risk management and internal control remedies to prevent future non-compliance and ensure adherence to Listing Rules Chapter 14 - The Board confirms its responsibility to maintain sound and effective risk management and internal control systems, having acted on identified deficiencies[4](index=4&type=chunk) - The company has implemented several remedial measures to ensure future compliance with Listing Rules Chapter 14, including strengthening internal control policies for notifiable transactions, providing internal training on Listing Rules for directors and management, hiring qualified staff to oversee future transactions and size test calculations, and seeking external professional advice for all proposed transactions[7](index=7&type=chunk)[5](index=5&type=chunk) [Share Option Scheme Update](index=2&type=section&id=Share%20Option%20Scheme%20Update) This section provides an update on the share option scheme, specifically detailing the number of options available for grant [Number of Share Options Available for Grant](index=2&type=section&id=Number%20of%20Share%20Options%20Available%20for%20Grant) The announcement details the number of share options available for grant under the scheme mandate and service provider sub-limits for fiscal year 2024, showing zero options at year-end Share Options Available for Grant | Category | January 1, 2024 | December 31, 2024 | | :--- | :--- | :--- | | Scheme Mandate Limit | 517,000,000 | 0 | | Service Provider Sub-limit | 51,700,000 | 0 | *Note: Numbers have been adjusted with reference to the share split effective December 10, 2024* [Other Information](index=3&type=section&id=Other%20Information) This section confirms the consistency of the annual report's other contents and lists the current composition of the Board of Directors [Concluding Remarks and Board Composition](index=3&type=section&id=Concluding%20Remarks%20and%20Board%20Composition) The announcement confirms the annual report's other contents remain unchanged, except for supplementary details, and lists the Board's composition as of the announcement date - All other information within the annual report remains unchanged, except for the supplementary details disclosed in this announcement[8](index=8&type=chunk) - As of the announcement date, the Board of Directors comprises eight members: three executive directors, two non-executive directors, and three independent non-executive directors[9](index=9&type=chunk)

Corporate Strategy and Development - The company has relocated its headquarters from Singapore to China to better align with its medical business development and future prospects[10]. - The company plans to diversify its business and expand into the Asia-Pacific region, including providing value-added services such as skills training[14]. - The company anticipates steady growth in medical device demand driven by an aging population and rising living standards in China[12]. - The company will broaden its product line and enhance R&D capabilities to improve competitiveness by 2025[12]. - The company aims to strengthen its position in the medical industry through resource integration and continuous product development[12]. - The group plans to enhance its development capabilities, expand its distribution network, and develop new products to strengthen its competitive position in the medical industry[20]. - The board is considering diversifying its business and expanding existing operations into the Asia-Pacific region, particularly China[24]. - The company is actively seeking more trade partners and market expansion opportunities amid economic challenges in 2025[14]. Financial Performance - The group's revenue increased from SGD 45.6 million in FY2023 to SGD 50.2 million in FY2024, representing a growth of 10%[25]. - Revenue from minimally invasive surgical solutions and related medical products rose from SGD 20.4 million in FY2023 to SGD 25.9 million in FY2024, an increase of SGD 5.5 million[26]. - The gross profit decreased from SGD 12.0 million in FY2023 to SGD 11.5 million in FY2024, with a gross margin decline from 26.4% to 22.8%[28]. - The group recorded a loss of SGD 18.3 million in FY2024, compared to a loss of SGD 4.1 million in FY2023, primarily due to share-based payments of SGD 13.2 million and expenses related to expanding its minimally invasive surgical solutions business in China[34]. - The group recorded an unrealized foreign exchange gain of SGD 0.3 million in FY2024 due to the appreciation of SGD against HKD and RMB[47]. - The financing costs increased by SGD 0.6 million in FY2024 due to new financing obtained during the year[32]. - The group has a total of 488 employees as of December 31, 2024, down from 694 employees in the previous year[58]. Corporate Governance - The company has adopted the corporate governance code as per the listing rules, demonstrating commitment to good governance practices[82]. - The board consists of eight members, including four executive directors and three independent non-executive directors, ensuring a balanced composition for independent judgment[88]. - The company has three independent non-executive directors, meeting the requirement that they constitute at least one-third of the board[89]. - All independent non-executive directors have confirmed their independence in accordance with the listing rules, ensuring compliance with governance standards[89]. - Continuous professional development programs have been provided to directors, enhancing their understanding of governance and responsibilities[92]. - The board is responsible for overseeing the management of the group's business affairs and overall performance, ensuring necessary financial and human resources are in place[84]. - The company has established various committees to delegate responsibilities, enhancing operational efficiency and accountability[84]. Risk Management and Compliance - The company has established a risk management and internal control system to ensure effective monitoring and evaluation of risks, with regular reports on risk assessment and management effectiveness[135]. - The company is committed to enhancing its risk management and internal control systems to ensure ongoing effectiveness[138]. - There are no significant deviations in risk management and internal controls across subsidiaries, and no major litigation risks have been reported[138]. - The company will continue to improve its compliance with financial reporting and legal regulations across all subsidiaries[138]. - The company has implemented a fair disclosure policy to ensure timely and equal access to information for shareholders and investors[140]. Shareholder Relations and Dividends - The board will keep shareholders informed of significant events as they occur[15]. - The company expresses gratitude to shareholders, customers, business partners, management, and employees for their ongoing support[16]. - The board does not recommend any dividend payment for FY2024, consistent with FY2023[35]. - The net proceeds from the listing amounted to HKD 82.6 million (approximately SGD 14.1 million), with planned allocations including SGD 20.5 million for registered capital injection into Jin Hai Medical[39]. - The net proceeds from the placement on October 18, 2023, were HKD 99 million, with a subscription price of HKD 1.60 per share, reflecting a discount of 19.6% to the market price at the time[43]. Leadership and Management - The company has established a strong leadership team with diverse backgrounds in banking, real estate, and technology sectors[71]. - The company is focused on strategic management and development in real estate, including property management and project oversight[68]. - The leadership team is expected to drive future growth through strategic decision-making and market expansion initiatives[75]. - The chairman and CEO roles are held by different individuals, ensuring a separation of responsibilities[106]. Environmental and Social Responsibility - The group has established an environmental management system to address its carbon footprint, particularly focusing on indirect greenhouse gas emissions from electricity usage[168]. - There were no instances of non-compliance with environmental laws and regulations during the fiscal year[168]. - The group made a total donation of SGD 108,000 during the year, consistent with the previous fiscal year[165]. Stock Options and Shareholder Equity - The company has adopted a share option scheme approved by shareholders on December 29, 2023, allowing eligible participants to acquire ownership interests in the company[188]. - A total of 128,603,750 stock options were granted on January 9, 2024, with an exercise price of HKD 2.54 per share[194]. - The stock options will vest in three tranches: 20% on April 30, 2025, 30% on April 30, 2026, and 50% on April 30, 2027[196]. - The total number of stock options granted to the executive director and CEO, Wang Zhenfei, is 25,850,000[199].